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Abstract: Natural sulphurated amino acids are cysteine and methionine. Their importance in biologi-
cal processes is largely known. Cysteine, plays a key role due to the thiol group, which represents a 
nucleophilic and easily oxidizable function. Synthetic methodologies to obtain Cysteine-, Methionine- 
and Seleno-Cysteine-Proline chimeras are strongly desirable and particularly appealing in the field of 
organic chemistry.  
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1. INTRODUCTION 
 In proteins, free Cysteine (Cys) has a hydrophilic charac-
ter, as hydrogen bond donor, while when covalently bonded 
each other, Cys residues have a crucial role in determining 
and stabilizing the conformation of protein and peptides [1, 
2]. Methionine (Met) contributes to conformational proper-
ties of proteins through the Met-aromatic motif, a hydropho-
bic interaction that provides an additional stabilization [3].  
 Structure’s modification on peptides is always responsi-
ble of changes in their biological activities, because a spe-
cific constraint, such as that imposed by unnatural amino 
acids, may destabilize the interactions between the ligand 
and the protein.  
 Methionine is an interesting amino acid residue in bio-
logically active peptides; its conformationally constrained 
analogues are subdivided into two, well-documented classes 
(Fig. 1) [4-8]. 
 Conformational profile of N-acetyl, N’-methylamide de-
rivatives of cis- and trans-3-methyl-proline shows an inverse 
-turn structure more stable than that of cis-3-methyl-proline 
[9], furthermore CC and NCO cyclizations are two 
complementary constraints.  
 The -stereocenter of proline amino acid determinates 
the amino acid side chain orientation in biologically active 
peptides binding to receptor [10].  
 To further delineate the molecular interactions of this C-
terminal amino acid with both binding sites of the human NK-
1 tachykinin receptor, Sugase et al. [11]
 
have designed  
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constrained analogs of methionine, i.e. 3-prolinomethionines. 
The resulting analogs completely lose NK-1 biological activity 
[12], a result which may come from the non-accurate fixed 
value of the 2 angle on the pyrrolidine ring. In contrast, 3-
prolinoamino acids [13], combine the proline constraint on the 
peptide backbone (fixed 1 angle) with the presence in position 
3 (or ) on the pyrrolidine ring of the native amino acid side 
chain with a flexible 2 angle.  
 Enomoto et al. [14]
 
investigated the structural modifica-
tions of N-mercaptoacyl-L-proline and (4R)-N-mercaptoacyl- 
thiazolidine-4-carboxylic acid to build efficient leukotriene 
A4 (LTA4) hydrolase inhibitors. The (2S)-3-mercapto-2-
methylpropionyl group was chosen for both of them (Fig. 2). 
 The insertion of 4-isopropylbenzylthio, 4-tert-
butylbenzylthio or 4-cyclohexylbenzylthio group with (S)-
configuration at the C-4 position of proline, gave strong 
LTA4 hydrolase inhibitors.  
 The syntheses of 3-proline-methionine and 4-proline-
methionine chimeras have been performed via Zinc-enolate 
cyclization and Mitsunobu reaction in diastereoselective and 
enantioselective way (Fig. 3). 
2. 3-SUBSTITUTED CYSTEINE-PROLINE AND ME-
THIONINE-PROLINE CHIMERAS SYNTHESES 
2.1. 5-Exo-Trig-Cyclization via Zinc Enolate 
 The first synthesis of a 3-proline-methionine chimera (3-
methylsulfanylmethyl-pyrrolidine-l,2-dicarboxylic acid di-
methyl ester) has been described by Udding et al. [15] which 
involves xanthate transfer cyclization of a glycine radical, 
leading to non-regiospecific and non-diastereoselective reac-
tion.  
 A more general strategy via Zinc-enolate cyclization, was 
reported by Karoyan and Chassing [16].  
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Fig. (2). Structures of N-mercaptoacyl-L-proline and (4R)-N-
mercaptoacylthiazolidine-4-carboxylic acid scaffolds. 
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Fig. (3). Schematic representation of possible synthetic approaches 
to Met-Pro and Cys-Pro chimeras. 
 
 The organozinc derivative was treated with iodine to give 
ethyl cis-3-iodomethyl-N-benzylprolinate, which was alkylated 
by the sodium salt of methanethiol to yield the cis-3-proline-
methionine analogs as racemic mixture. A one-pot procedure 
could be also applied modifying the carbanionic species and 
using an electrophilic sulfur donor, so as the stereogenic cen-
ter on the N-protecting group generates an asymmetric C-2 
carbon atom center.  
 Following Karoyan and Chassing also described the con-
version of the N-(o-methylbenzyl)-prolinomethionine into N-
(vinyloxycarbonyl)-prolinomethionine (Voc(P3)Met), and 
into N-(tert-butoxycarbonyl)-prolinomethionine (Boc(P3)Met) 
(Scheme 1) [17].
 
 The (-)/(+) [But-3-enyl-(1-phenyl-ethyl)-amino]-acetic 
acid ethyl or benzyl ester (-)-1 and (+)-1 were prepared by 
alkylation of (-) or (+)--methylbenzylamine with 4-
bromobutene and ethylbromoacetate or benzylbromoacetate 
respectively, in DMSO.  
 The lithium enolate of (-)-1 was transmetallated (3 eq. of 
dried ZnBr2 at -90°C) to yield cis diastereoselective cycliza-
tion, the reaction mixture was cooled to 0°C and the second 
transmetallation reaction was carried out (1.2 eq. of CuCN 
1M, LiCl in THF at 0°C for 10 min.), then (S)-methyl 
methanesulfonothiolate was added.  
 Easy cleveage of the cuprozinc compound was achieved 
giving the 3-methyl-sulfanylmethyl-l-(1-phenyl-ethyl)-pyrro- 
lidine-2-carboxylic acid ethyl ester 2 in 2S,3R configuration. 
 Olofson et al. [18] used vinylchloroformate for N-
dealkylations on product 2, despite the slow reaction’s rate, 
then voc group was removed from 3 by HCl in dioxane.  
 Tert-butoxycarbonyl (N-Boc) protection and saponification 
gave (2S,3R)-Boc 3-proline-methionine 4 as crude mixture, 
which was following purified by silica gel chromatography.  
 An alternative route was proposed starting from (+)--
methylbenzylamine to give (2R,3S)-benzyl-Voc-3-proline-
methioninate 5, which was deprotonated by LDA in THF at -
78 °C obtaining an inversion of configuration at the C car-
bon over 90% (as determined by NMR).  
 Enantiomerically pure (2S,3S)-benzyl-Voc-3-proline-
methioninate 6 was isolated after flash chromatography. 
Boc2O protection and saponification gave the (2S,3S)-Boc 3-
proline-methionine 7.  
 As a continuation of their studies concerning solid-phase 
amino-Zinc-enolate cyclization, Karoyan et al. [19]
 
explored 
the iodo derivative 8 functionalization (Scheme 2). 
 Compound 8 was reacted with two kinds of nucleophiles 
sodium thiophenate and p-nitrophenol in DMF, at 50°C. In 
the first case, compound 10 was characterized by mass spec-
troscopy after cleavage of 9 from the resin while in the sec-
ond case, 2 eq. of nucleophile were used with K2CO3 giving 
nucleophilic substitution of the halogen atom and cleavage 
of the product from the resin. 
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Fig. (1). Conformationally constrained methionines. 
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Scheme 1. Synthesis of (2S, 3R)- and (2S, 3S)-prolinomethionine 
[17]. 
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Scheme 2. Functionalization of the iodo derivative [19]. 
 
 Basic conditions applied during the work-up of the reac-
tion cleaved the p-nitrophenol ester providing compounds 11 
and 12. 
2.2. Via Dihydroproline Intermediate Formation 
 Kolodziej et al. [20] reported the synthesis of protected 
cysteine-proline chimeras to the synthesis of D,L-N-Boc-3-
mercapto-proline (D,L-15) (Scheme 3). 
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Scheme 3. Synthesis of 3-substituted proline reported by Kolodziej 
et al. [20]. 
 
 Conjugate addition of 4-methylbenzylmercaptan to 2,3-
dehydroproline derivative 13, [21] and hydrolysis in acid 
conditions, provided the trans-diastereomer 14 following 
ripetitive crystallizations, in 52% yield. Compound 14 was 
protected with Boc2O to give derivative 15 as cyclohexy-
lamine salt in 92% yield. In a similar manner, the cis-isomers 
were also obtained (Scheme 4). 
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Scheme 4. Synthesis of diastereomeric mixture of protected 3-
substituted proline [20]. 
 
 The 3-bromo-l,2-dehydroproline derivative 16 was de-
scribed by Hausler and Schmidt [22], and used to react with 
4-methylbenzylmercaptan in aqueous sodium hydroxide; 
diastereoselective reduction with NaBH4 provided the cis-
isomer D,L-17 in an overall yield of 37%.  
3. 4-SUBSTITUTED CYSTEINE-PROLINE AND ME-
THIONINE-PROLINE CHIMERAS SYNTHESES 
3.1. Mitsunobu Reaction 
 Selective CCK-B agonist can be prepared by substitution 
of the 
31
Met residue in Boc-CCK4 ((Boc-Trp
30
-Met
31
-Asp
32
-
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Phe
33
-NH2) with trans-3-propyl-proline. At this regard, 
Kolodziej et al. [20] synthesized different Ac-CCK4 analogs 
containing 3- and 4-(alkylthio)-substituted proline deriva-
tives. A high-yielding synthetic strategy was developed to 
achieve the S-methylated derivatives 23 and 25 (Scheme 5). 
 Reaction of compound 20 with thiolacetic acid under 
Mitsunobu conditions is the key transformation, to provide 
derivative 21 in 85% yield [23].  
 Derivative 23 was obtained in a one-pot reaction’s se-
quence [23] involving two selective hydrolysis and alkyla-
tion, in 60% overall yield from 19. Mitsunobu inversion of 
the C-4 carbon of 20 was performed using formic acid, fol-
lowed by hydrolysis of the formate ester to yield 22 in 64%. 
Then 25 was obtained in an overall yield of 45% from 19, 
following the reaction’s sequence described above. Recently 
Mollica et al. [24] investigated new fMLF analogs incorpo-
rating chimeric L-proline-methionine residues, namely the 
homochiral cis-4(S)-methylthio-(S)-proline 28 and the het-
erochiral trans-4(R)-methylthio-(S)-proline 35, in which -
thiomethyl-ether functionality is preserved. Cis- and trans-4-
methylthio-proline derivatives can be prepared following 
different approaches [25].  
 To obtain N-Boc-cis-4(S)-methylthio-(S)-proline 28 and 
N-Boc-trans-4(R)-methylthio-(S)-proline 35, the N-protected 
cis-analog 28 was prepared from 4-hydroxy-trans-proline 29 
treating the corresponding N-Boc-trans-4-mesylate 26 with 
potassium thioacetate, followed by hydrolysis of the deriva-
tive 27 and alkylation of the thiol group (Scheme 6). 
 The N-Boc derivative 29 was prepared to build N-Boc-
trans-analog 34 (Scheme 7).  
 In this case, two configurational inversions at C-4 oc-
curred; the first involved the formation of the 4-oxo-analog 
30 which, after stereoselective reduction with NaBH4, gave 
the N-Boc-(2S,4S)-cis-isomer 31.  
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Scheme 6. Synthesis of cis-4(S)-methylthio-(S)-proline by Mollica 
et al. [24]. 
4. 4-SELENO-CYSTEINE-PROLINE CHIMERAS 
SYNTHESES 
4.1. Mitsunobu Reaction 
 The preparation of Seleno-Cysteine-Pro chimeras is par-
ticularly interesting since its use in native chemical ligation 
(NCL) in several papers [26-29].  
 One of the first attempt to synthesize these chimeras was 
done by Rüeger and Benn for the (S)-3,4-dehydroproline 
starting from (2S,4R)-4-hydroxyproline [30], considering 
that selenoxide elimination can be regioselective if the re-
quired 3-ene function could be introduced (Scheme 8).  
 This protocol was applied successively by Robinson et al. 
[31]
 
for the synthesis of a series of epoxyprolines and ami-
nohydroprolines.  
 For this purpose, 3,4-dehydro-L-proline derivative was 
prepared from trans-hydroxy-L-proline 37 using a modified 
version of the method reported by Rüeger and Benn (Scheme 
9) [30]. 
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Scheme 5. Synthesis of 4-substituted Cys-Pro reported by Kolodziej et al. [20]. 
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Scheme 7. Synthesis of trans-4(R)-methylthio-(S)-proline [24]. 
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Scheme 8. Schematic representation of protocol applied by Rüeger 
and Benn [30]. 
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Scheme 9. Synthesis of intermediate product for Rüeger’s proce-
dure [30]. 
 
 Treatment of derivative 42 with tosyl chloride/pyri- 
dine failed to give tosylate 44 in good yield. Then 1-
(toluenesulphonyl)-3-methylimidazolium triflate 43 was cho-
sen to prepare product 44 in acceptable yield. Reaction of 44 
with PhSeSePh/NaBH4 in tert-butanol furnished 45 without 
transesterification. Durek and Alewood have studied the 
conversion of thioesters to selenoesters to give highly reac-
tive C-terminal ligation partners [32]. Also Metanis et al. 
[33] have described the ligation and the deselenization of 
peptide-feature N-terminal selenocysteine residues. Thus 
trans-seleno-proline, was synthesized for the first time 
(Scheme 10). 
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Scheme 10. Synthesis of trans-seleno-proline [30]. 
 Beginning with the commercially available pyrrolidine 
46, Mitsunobu inversion gave the cis-iodo-proline 47, in 
good yield. Treatment with selenobenzoic acid provided 
compound 48 in 84% yield. Removal of the benzoate and 
saponification occurs in concert to give N-Boc seleno-
proline dimer 49, in 79% yield which was finally removed 
under acidic conditions to afford oxidatively dimerized 50.  
4.2. SN2 Reaction 
 Starting from 4-hydroxylproline, Caputo et al. [34]
 
re-
ported a new procedure to prepare sulphur and selenium con-
taining bis -amino acids. The existing hydroxyl group of 
trans-4-hydroxy-L-proline was involved in SN2 process, for 
which inversion of C-4 configuration occurred. Although 
trans configuration was maintained transforming the hydroxyl 
group either into its tosyl ester or by substitution with an io-
dine complex, giving the cis-4-iodo-L-proline. Cysteinyl nu-
cleophile attack provided trans-4-(S)-cysteinyl-L-proline 53 
from compound 51 and cis-4-(S)-cysteinyl-L-proline 54 from 
derivative 52; diastereomeric trans/cis 4-selenocysteinyl-L-
prolines 55 and 56 were finally obtained with the addition of 
selenocysteinyl nucleophile (Scheme 11) [35]. 
5. CONCLUSION 
 This review is focused on Met, Cys, and Cys-Seleno 
Proline chimeras. The most important synthetic strategies 
reported in literature to prepare these chimeric compounds 
have been reported and discussed. They are particularly im-
portant in peptidomimetics design; for example, Winiewski 
reported a small library of oxytocin analogues [36], which 
show selectivity to vasopressin receptors and present several 
chemical modification, including the introduction of trans-4-
SMe-Pro residue in peptide 57 (Fig. 4). 
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Scheme 11. Synthesis of bis -amino acids from 4-hydroxylproline 
by Caputo et al. [34]. 
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Fig. (4). An oxytocin analog containing a Met-Pro chimera residue 
[36]. 
 
 This class of compounds can be considered central in the 
field of peptide-based drug discovery [37], due to the re-
markable effects of proline and cysteine on peptides secon-
dary structures. 
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